FDA committee backs GSK’s multiple myeloma drug
If approved, belantamab mafodotin will be a first-in-class anti-BCMA therapy for relapsed/refractory multiple myeloma
Read More
Tag: DREAMM
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
